Senti Biosciences, Inc. — Department of Health and Human Services SBIR Phase II: 414
Senti Biosciences, Inc. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,999,993
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 414
- Solicitation
- PHS2021-1
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
The therapeutic administration of chimeric antigen receptor (CAR)-based cell therapies has considerably advanced the treatment of certain cancers. Unfortunately, the successes of CAR-based cell therapies have not yet translated to treatment of acute myeloid leukemia (AML), likely due to the lack of a suitable lineage antigen target. Due to their nonrestrictive expression, most AML antigens are also expressed on hematopoietic stem cells (HSCs), and thus on-target/off-tumor effects of the therapy may lead to the ablation of hematopoietic stem/progenitor cells, causing significant and life-threatening myelotoxicity and prolonged cytopenia. While there are currently dozens of clinical trials underway for various CAR-based therapies in AML patients, no treatment has yet demonstrated the ability to curb on-target/off-tumor killing of healthy HSCs.